DK1581535T5 - Pyrrolopyridazinderivater - Google Patents

Pyrrolopyridazinderivater

Info

Publication number
DK1581535T5
DK1581535T5 DK03789642T DK03789642T DK1581535T5 DK 1581535 T5 DK1581535 T5 DK 1581535T5 DK 03789642 T DK03789642 T DK 03789642T DK 03789642 T DK03789642 T DK 03789642T DK 1581535 T5 DK1581535 T5 DK 1581535T5
Authority
DK
Denmark
Prior art keywords
pyrrolopyridazine
Prior art date
Application number
DK03789642T
Other languages
Danish (da)
English (en)
Other versions
DK1581535T3 (da
Inventor
Yoshito Abe
Makoto Inoue
T Mizutani
Kozo Sawada
Kazuhiko Ohne
M Okumura
Yuki Sawada
K Imamura
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2003900189A external-priority patent/AU2003900189A0/en
Priority claimed from AU2003903628A external-priority patent/AU2003903628A0/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of DK1581535T3 publication Critical patent/DK1581535T3/da
Application granted granted Critical
Publication of DK1581535T5 publication Critical patent/DK1581535T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK03789642T 2003-01-09 2003-12-26 Pyrrolopyridazinderivater DK1581535T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003900189A AU2003900189A0 (en) 2003-01-09 2003-01-09 Heterocyclic derivatives
AU2003903628A AU2003903628A0 (en) 2003-07-14 2003-07-14 Pyrrolopyridazine derivatives
PCT/JP2003/017091 WO2004063197A1 (fr) 2003-01-09 2003-12-26 Derives de pyrrolopyridazine

Publications (2)

Publication Number Publication Date
DK1581535T3 DK1581535T3 (da) 2008-02-11
DK1581535T5 true DK1581535T5 (da) 2009-12-21

Family

ID=32714072

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03789642T DK1581535T5 (da) 2003-01-09 2003-12-26 Pyrrolopyridazinderivater

Country Status (22)

Country Link
US (2) US7153854B2 (fr)
EP (1) EP1581535B3 (fr)
JP (1) JP4671104B2 (fr)
KR (1) KR101026819B1 (fr)
AR (1) AR042833A1 (fr)
AT (1) ATE376549T1 (fr)
BR (1) BR0317358A (fr)
CA (1) CA2513081C (fr)
CY (1) CY1107084T1 (fr)
DE (1) DE60317102T3 (fr)
DK (1) DK1581535T5 (fr)
ES (1) ES2291729T7 (fr)
HK (1) HK1088900A1 (fr)
IL (1) IL169500A0 (fr)
MX (1) MXPA05007462A (fr)
NO (1) NO20053748L (fr)
NZ (1) NZ541232A (fr)
PL (1) PL378245A1 (fr)
PT (1) PT1581535E (fr)
RU (1) RU2328499C2 (fr)
TW (1) TWI332004B (fr)
WO (1) WO2004063197A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063197A1 (fr) 2003-01-09 2004-07-29 Fujisawa Pharmaceutical Co., Ltd. Derives de pyrrolopyridazine
US7030112B2 (en) * 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2006004191A1 (fr) * 2004-07-05 2006-01-12 Astellas Pharma Inc. Derivés de pyrrolopyridazine qui inhibent la pde iv et le tnf alpha
ATE415400T1 (de) * 2004-07-05 2008-12-15 Astellas Pharma Inc Pyrazolopyridinderivate
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
JP2009114123A (ja) * 2007-11-06 2009-05-28 Astellas Pharma Inc ２−アシル−１−アミノピロール化合物の新規製造法
JP2011504505A (ja) 2007-11-21 2011-02-10 デコード ジェネティクス イーエイチエフ 肺および心血管障害を治療するためのビアリールｐｄｅ４抑制剤
BRPI0906838A2 (pt) 2008-01-11 2015-07-14 Novartis Ag Pirimidinas como inibidores de quinase
US20110105510A1 (en) * 2008-06-17 2011-05-05 Hiroshi Ishikawa Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
WO2010036380A1 (fr) 2008-09-26 2010-04-01 Intellikine, Inc. Inhibiteurs hétérocycliques de kinases
WO2010059836A1 (fr) * 2008-11-20 2010-05-27 Decode Genetics Ehf Composés bicycliques substitués à pont aza pour maladie cardiovasculaire et du système nerveux central
EP2424521A4 (fr) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
CA2807317C (fr) * 2010-04-23 2021-01-19 Steam Tech, Llc Systeme d'essuie-glace
MX2012013824A (es) * 2010-05-28 2013-03-12 Biocryst Pharm Inc Compuestos heterociclicos como inhibidores de cinasa janus.
ES2583528T3 (es) 2010-09-07 2016-09-21 Astellas Pharma Inc. Compuesto de pirazoloquinolina
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
JP5988941B2 (ja) * 2012-09-20 2016-09-07 富士フイルム株式会社 有機銅錯体、有機銅錯体溶液、銅酸化物薄膜、銅酸化物薄膜の製造方法、および、化合物
US10434132B2 (en) * 2013-06-04 2019-10-08 Academia Sinica Galactolipids-enriched plant extracts and the uses thereof
WO2019099755A1 (fr) * 2017-11-17 2019-05-23 Academia Sinica Hybrides de bis(hydroxyméthyl) pyrrolophtalazine, leurs procédés de préparation et leurs utilisations
CN113166160B (zh) * 2018-10-17 2023-12-19 苏文生命科学有限公司 作为毒蕈碱型m1受体正向别构调节剂的吡咯并哒嗪衍生物
WO2020191091A1 (fr) 2019-03-19 2020-09-24 Boehringer Ingelheim Animal Health USA Inc. Composés d'aza-benzothiophène et d'aza-benzofurane anthelminthiques
BR112022024156A2 (pt) 2020-05-29 2023-02-14 Boehringer Ingelheim Animal Health Usa Inc Compostos heterocílicos antelmínticos
AU2022377394A1 (en) 2021-11-01 2024-06-13 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic pyrrolopyridazine compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018903A1 (fr) * 1990-05-25 1991-12-12 Fujisawa Pharmaceutical Co., Ltd. Composes de pyrrolopyridazine
CN1302300A (zh) 1998-05-21 2001-07-04 盐野义制药株式会社 吡咯并[1,2－b]哒嗪sPLA2抑制剂
IT1303272B1 (it) * 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
FR2792938B1 (fr) * 1999-04-28 2001-07-06 Warner Lambert Co NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV
ES2317889T3 (es) * 2000-03-01 2009-05-01 Janssen Pharmaceutica Nv Derivados de tiazolilo 2,4-disustituido.
US7026318B2 (en) * 2000-06-29 2006-04-11 Shionogi & Co., Ltd. Compounds exhibiting X-type sPLA2 inhibiting effect
EP1363910B1 (fr) * 2000-11-17 2006-03-01 Bristol-Myers Squibb Company Methodes de traitement des pathologies liees a la kinase p38 et composes de pyrrolotiazine utilises en tant qu'inhibiteurs de la kinase
TWI312347B (en) * 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
US20040254189A1 (en) * 2001-08-23 2004-12-16 Hideaki Nagaya Jnk inhibitors
US6900208B2 (en) * 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
WO2004063197A1 (fr) 2003-01-09 2004-07-29 Fujisawa Pharmaceutical Co., Ltd. Derives de pyrrolopyridazine

Also Published As

Publication number Publication date
MXPA05007462A (es) 2006-01-27
RU2005125209A (ru) 2006-01-27
CA2513081A1 (fr) 2004-07-29
NO20053748D0 (no) 2005-08-04
EP1581535A1 (fr) 2005-10-05
JP2006515597A (ja) 2006-06-01
EP1581535B3 (fr) 2009-09-02
ES2291729T7 (es) 2010-03-31
PT1581535E (pt) 2007-12-12
EP1581535B9 (fr) 2008-03-19
KR101026819B1 (ko) 2011-04-04
KR20050092738A (ko) 2005-09-22
DE60317102T3 (de) 2010-02-18
US7153854B2 (en) 2006-12-26
NZ541232A (en) 2008-02-29
US7317009B2 (en) 2008-01-08
EP1581535B1 (fr) 2007-10-24
TWI332004B (en) 2010-10-21
ATE376549T1 (de) 2007-11-15
NO20053748L (no) 2005-10-07
ES2291729T3 (es) 2008-03-01
CA2513081C (fr) 2011-04-19
JP4671104B2 (ja) 2011-04-13
AR042833A1 (es) 2005-07-06
DE60317102D1 (de) 2007-12-06
BR0317358A (pt) 2005-12-13
US20050075342A1 (en) 2005-04-07
DE60317102T2 (de) 2009-01-29
DK1581535T3 (da) 2008-02-11
HK1088900A1 (en) 2006-11-17
WO2004063197A1 (fr) 2004-07-29
TW200418861A (en) 2004-10-01
US20060270678A1 (en) 2006-11-30
IL169500A0 (en) 2007-07-04
PL378245A1 (pl) 2006-03-20
CY1107084T1 (el) 2012-10-24
RU2328499C2 (ru) 2008-07-10

Similar Documents

Publication Publication Date Title
DK1581535T5 (da) Pyrrolopyridazinderivater
DE602004031657D1 (de) Einführstützsystem
DE502004001683D1 (de) Kabelführung
SE0302091L (sv) Genomföring
DK1610609T3 (da) Fluid-opvarmer
AT502792A5 (de) Düsenanpressvorrichtung
DE502004011106D1 (de) 6-arylmethyl-substituierte pyrazolopyrimidine
DE502004007911D1 (de) Wischblatt
DE112004000620D2 (de) Struktoguss
DE502004000672D1 (de) Pigmentpreparationen
NO20030424L (no) Bronnhodeplattform
DE502004001524D1 (de) Hydrolager
ATA662003A (de) Trink-mundstück
ATE446959T1 (de) Chromenonindole
DE502004001629D1 (de) Bremsenprüfstand
DE502004003122D1 (de) Hydrolager
DE502004002978D1 (de) N-biarylamide
FR2864125B1 (fr) Caillebotis
DE502004000518D1 (de) Mitgängergabelhubwagen
DE502004006563D1 (de) Brieftaubenkonstatiersystem
DE10394329D2 (de) Mäanderstent
DE502004005162D1 (de) Leistungsregelvorricthung
ATE406350T1 (de) Prolinylarylacetamide
DE112004002227D2 (de) Nietverarbeitungsgerät
DE502004007251D1 (de) En 2-arylpropenalen